Mechelen, Belgium and Galashiels, Scotland; 25 July 2007 - Galapagos NV (Euronext & LSE: GLPG) announced today the achievement of the second milestone under the collaboration with Novartis in antibodies for bone-related diseases. Today’s milestone triggers a payment of $1 million to Galapagos. Galapagos will pay $750,000 of this amount to ProStrakan as part of their December 2006 agreement.
